Sight Sciences (SGHT) EVP sale covers RSU tax in small stock sale
Rhea-AI Filing Summary
Sight Sciences executive Brenton Taylor, EVP of Operations & R&D, reported a small sale of company stock mainly to cover taxes from vesting equity. On January 6, 2026, he sold 619 shares of Sight Sciences common stock at a weighted average price of $7.48 per share, through multiple trades priced between $7.39 and $7.67. After this tax-related sale, he directly holds 170,212 shares of the company’s common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 619 | $7.48 | $5K |
Footnotes (1)
- Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $7.39 to $7.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
FAQ
What insider transaction did Sight Sciences (SGHT) report for Brenton Taylor?
Brenton Taylor, EVP of Operations & R&D at Sight Sciences, reported selling 619 shares of the company’s common stock on January 6, 2026.
What was the sale price in Brenton Taylors Form 4 for Sight Sciences (SGHT)?
The weighted average price for the 619 shares sold was $7.48 per share, with individual trades executed between $7.39 and $7.67.
Is the reported Sight Sciences (SGHT) insider transaction direct or indirect ownership?
The Form 4 classifies Brenton Taylors ownership of the reported shares as direct (D) ownership.
What type of security did Brenton Taylor trade in the Sight Sciences (SGHT) filing?
The transaction involved common stock of Sight Sciences, with no derivative securities reported in the provided tables.